Recommended for restricted use within NHS Scotland.
REASONS FOR ADVICE.
Pegylated interferon alfa-2a is an appropriate treatment for the treatment of adult patients with chronic hepatitis C under the overall supervision of specialists experienced in the management of this disorder. This treatment involves a weekly injection from a pre-filled syringe that reduces inconvenience to patients whilst increasing the response rate over interferon alfa-2a alone or in combination with Ribavirin.
Download detailed advice21KB (PDF)
- Medicine name:
- Pegylated interferon alfa-2a (Pegasys®)
- SMC ID:
- Chronic hepatitis C
- Pharmaceutical company
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 06 September 2002